{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:55:35Z","timestamp":1791248135398,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ard.2026.06.024","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T20:03:21Z","timestamp":1786565001000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter P","family":"Maksymowych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro M","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zubrzycka-Sienkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Z\u00e1vada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1491-0494","authenticated-orcid":false,"given":"Lien","family":"Gheyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Mangili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Mutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck-Olivier","family":"Le Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.06.024_bib0001","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","article-title":"Axial spondyloarthritis","volume":"405","author":"Navarro-Comp\u00e1n","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2026.06.024_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003504","article-title":"International Map of Axial Spondyloarthritis (IMAS): results from the perspective of 5557 patients from 27 countries around the globe","volume":"10","author":"Garrido-Cumbrera","year":"2024","journal-title":"RMD Open."},{"key":"10.1016\/j.ard.2026.06.024_bib0003","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/rheumatology\/keab544","article-title":"Age at onset in axial spondyloarthritis around the world: data from the Assessment in SpondyloArthritis international Society Peripheral Involvement in Spondyloarthritis study","volume":"61","author":"Boel","year":"2022","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ard.2026.06.024_bib0004","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s12325-022-02064-x","article-title":"Treatment failure in axial spondyloarthritis: insights for a standardized definition","volume":"39","author":"Juanola","year":"2022","journal-title":"Adv Ther."},{"key":"10.1016\/j.ard.2026.06.024_bib0005","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ard.2025.01.035","article-title":"The Assessment of SpondyloArthritis International Society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis","volume":"84","author":"Poddubnyy","year":"2025","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.06.024_bib0006","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/rheumatology\/kead494","article-title":"Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching","volume":"63","author":"Linde","year":"2023","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ard.2026.06.024_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70197","article-title":"Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in patients with axial spondyloarthritis in the United States: persistence, variables associated with persistence, and dosing variations","volume":"34","author":"Dubreuil","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.ard.2026.06.024_bib0008","series-title":"Xeljanz \u2013 Summary of Product Characteristics [Internet]","year":"2017"},{"key":"10.1016\/j.ard.2026.06.024_bib0009","series-title":"Xeljanz \u2013 Prescribing Information [Internet]","year":"2018"},{"key":"10.1016\/j.ard.2026.06.024_bib0010","series-title":"Rinvoq \u2013 Summary of Product Characteristics [Internet]","year":"2019"},{"key":"10.1016\/j.ard.2026.06.024_bib0011","series-title":"Rinvoq \u2013 Prescribing Information [Internet]","year":"2025"},{"key":"10.1016\/j.ard.2026.06.024_bib0012","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.ard.2026.06.024_bib0013","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.06.024_bib0014","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","article-title":"Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group","volume":"75","author":"Lambert","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.06.024_bib0015","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/art.21337","article-title":"Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ard.2026.06.024_bib0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3899\/jrheum.140519","article-title":"Development and preliminary validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging sacroiliac joint structural score","volume":"42","author":"Maksymowych","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ard.2026.06.024_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152884","article-title":"Rheumatologist and patient perspectives on axial spondyloarthritis management and treatment satisfaction in Europe","volume":"76","author":"Baraliakos","year":"2026","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.ard.2026.06.024_bib0018","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.06.024_bib0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-024-03441-3","article-title":"Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study","volume":"27","author":"Van den Bosch","year":"2025","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.ard.2026.06.024_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002165","article-title":"Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST","volume":"8","author":"Braun","year":"2022","journal-title":"RMD Open."},{"key":"10.1016\/j.ard.2026.06.024_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20090","article-title":"Tumour necrosis factor-\u03b1 inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation","volume":"20","author":"Corbett","year":"2016","journal-title":"Health Technol Assess."},{"key":"10.1016\/j.ard.2026.06.024_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002302","article-title":"Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter","volume":"8","author":"Li","year":"2022","journal-title":"RMD Open."},{"key":"10.1016\/j.ard.2026.06.024_bib0023","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13075-017-1342-9","article-title":"MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation","volume":"19","author":"Maksymowych","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.ard.2026.06.024_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.700260","article-title":"Active inflammatory and chronic structural damages of sacroiliac joint in patients with radiographic axial spondyloarthritis and non-radiographic axial spondyloarthritis","volume":"12","author":"Tu","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.ard.2026.06.024_bib0025","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.06.024_bib0026","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.06.024_bib0027","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.ard.2026.06.024_bib0028","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.06.024_bib0029","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.06.024_bib0030","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.ard.2026.06.024_bib0031","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/apt.17674","article-title":"Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE","volume":"58","author":"Schreiber","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.ard.2026.06.024_bib0032","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/apt.18158","article-title":"Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4\u2009years of follow-up in the SELECTION open-label long-term extension study","volume":"60","author":"Feagan","year":"2024","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.ard.2026.06.024_bib0033","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/ard-2024-225759","article-title":"Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years","volume":"83","author":"Burmester","year":"2024","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.06.024_bib0034","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.06.024_bib0035","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/acr2.11669","article-title":"Upadacitinib in active non-radiographic axial spondyloarthritis: 1-year data from a double-blind, randomized, placebo-controlled, phase 3 trial","volume":"6","author":"Van den Bosch","year":"2024","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.ard.2026.06.024_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005033","article-title":"Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes","volume":"11","author":"Mariette","year":"2025","journal-title":"RMD Open."},{"key":"10.1016\/j.ard.2026.06.024_bib0037","series-title":"The burden of axial spondyloarthritis: a global patient perspective [Internet]","year":"2024"},{"key":"10.1016\/j.ard.2026.06.024_bib0038","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ard.2025.11.010","article-title":"Evaluation of the placebo and treatment effect overtime in randomised clinical trials evaluating the efficacy of biologics in axial spondyloarthritis: systematic review and meta-analysis","volume":"85","author":"Perrot","year":"2026","journal-title":"Ann Rheum Dis."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:55:06Z","timestamp":1787691306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726003729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"alternative-id":["S0003496726003729"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.06.024","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Alfasigma S.p.A. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}